Analysts expect Liquidia Technologies Inc (NASDAQ:LQDA) to post sales of $690,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Liquidia Technologies’ earnings. The lowest sales estimate is $600,000.00 and the highest is $770,000.00. The firm is expected to issue its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Liquidia Technologies will report full year sales of $2.42 million for the current year, with estimates ranging from $1.90 million to $2.93 million. For the next financial year, analysts expect that the company will post sales of $2.52 million, with estimates ranging from $2.50 million to $2.54 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Liquidia Technologies.
Liquidia Technologies (NASDAQ:LQDA) last announced its earnings results on Thursday, May 2nd. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.27). Liquidia Technologies had a negative net margin of 1,964.76% and a negative return on equity of 222.47%.
Shares of LQDA stock opened at $8.67 on Friday. Liquidia Technologies has a fifty-two week low of $8.01 and a fifty-two week high of $38.46. The stock has a market cap of $160.14 million and a P/E ratio of -1.15. The company has a quick ratio of 5.57, a current ratio of 5.57 and a debt-to-equity ratio of 0.46.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in shares of Liquidia Technologies during the first quarter valued at $32,000. New York State Common Retirement Fund purchased a new stake in Liquidia Technologies in the 4th quarter worth about $96,000. TIAA CREF Investment Management LLC purchased a new stake in Liquidia Technologies in the 3rd quarter worth about $336,000. Bank of New York Mellon Corp purchased a new stake in Liquidia Technologies in the 4th quarter worth about $403,000. Finally, Geode Capital Management LLC lifted its stake in Liquidia Technologies by 50.1% in the 4th quarter. Geode Capital Management LLC now owns 49,319 shares of the company’s stock worth $1,068,000 after acquiring an additional 16,453 shares in the last quarter. 56.37% of the stock is owned by institutional investors and hedge funds.
Liquidia Technologies Company Profile
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.